Search results (179)
« Back to PublicationsThe circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation.
Journal article
Dillman A. et al, (2026), EBioMedicine, 124
Housing and health inequalities: why is housing on the periphery of health and welfare policy?
Journal article
Harding A. et al, (2026), Frontiers in Environmental Health, 5
Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.
Journal article
Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
Journal article
Sooi K. et al, (2025), Br J Cancer, 133, 896 - 908
Precision Prevention Studies: A Targeted Approach to Cancer Prevention.
Journal article
Blagden SP. et al, (2025), Cancer Prev Res (Phila), 18, 499 - 507
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Journal article
Plummer R. et al, (2025), Cell Rep Med, 6
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Journal article
Kazmi F. et al, (2025), Cochrane Database Syst Rev, 3
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.
Journal article
Liu J. et al, (2025), J Clin Oncol, 43, 735 - 747
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorder.
Journal article
Chettle J. et al, (2024), HGG Adv, 5
Access divergence to new cancer medicines in the United Kingdom.
Journal article
Lythgoe MP. et al, (2024), Eur J Cancer, 207
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Journal article
Spiliopoulou P. et al, (2024), J Exp Clin Cancer Res, 43
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Journal article
Janku F. et al, (2024), Cancers (Basel), 16
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.
Journal article
Dixon-Zegeye M. et al, (2024), Trials, 25
Early phase antitumour clinical trials and palliative medicine.
Journal article
Virani F. et al, (2024), BMJ Support Palliat Care, 13, e780 - e781
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies.
Journal article
Lythgoe MP. et al, (2023), Lancet Oncol, 24, 963 - 966